Edition:
United States

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

84.72EUR
11:35am EDT
Change (% chg)

€-0.28 (-0.33%)
Prev Close
€85.00
Open
€85.60
Day's High
€86.46
Day's Low
€84.48
Volume
283,726
Avg. Vol
400,541
52-wk High
€98.82
52-wk Low
€61.88

Latest Key Developments (Source: Significant Developments)

Galapagos Q1 Operating Loss Widens To 32.0 Million Euros
Wednesday, 25 Apr 2018 04:02pm EDT 

April 25 (Reuters) - GALAPAGOS NV ::Q1 REVENUE EUR 44.8 MILLION VERSUS EUR 39.9 MILLION YEAR AGO.Q1 OPERATING LOSS EUR 32.0 MILLION VERSUS LOSS OF EUR 11.2 MILLION YEAR AGO.Q1 NET LOSS FOR THE PERIOD EUR 37.3 MILLION VERSUS LOSS OF EUR 13.6 MILLION YEAR AGO.CASH AND CASH EQUIVALENT AT END-Q1 EUR 1.11 BILLION VERSUS EUR 0.95 BILLION YEAR AGO.AIMS TO REPORT TOPLINE RESULTS WITH FINCH 2 (RHEUMATOID ARTHRITIS) AND EQUATOR (PSORIATIC ARTHRITIS) IN 2018.AIMS TO REPORT TOPLINE RESULTS WITH TORTUGA (ANKYLOSING SPONDILITIS) FILGOTINIB STUDY IN 2018.IN 2018, AIMS TO REPORT DECISION TO CONTINUE TO PHASE 3 IN SELECTION (ULCERATIVE COLITIS).IN 2018, CO'S PARTNER GILEAD TO COMPLETE RECRUITMENT OF REMAINING RA PHASE 3 STUDIES WITH FILGOTINIB.IN 2018, FOR CYSTIC FIBROSIS, EXPECTS READOUT OF PELICAN PATIENT STUDY WITH GLPG2737.IN 2018, FOR CYSTIC FIBROSIS, EXPECTS INTERIM READOUT WITH FIRST TRIPLE COMBINATION THERAPY IN FALCON.TO START DOSING ISABELA LATER IN 2018.TO INITIATE PHASE 2 STUDIES WITH GLPG1205 (IPF), ADDITIONAL CF TRIPLE COMBINATION, GLPG1972 (OSTEOARTHRITIS), AND MOR106 (ATOPIC DERMATITIS) LATER IN 2018.EXPECTS OPERATIONAL CASH BURN BETWEEN EUR 220 MILLION AND EUR 240 MILLION IN 2018.  Full Article

Galapagos NV Q1 Basic And Diluted Loss Per Share EUR 0.73
Wednesday, 25 Apr 2018 04:02pm EDT 

April 25 (Reuters) - Galapagos NV ::GALAPAGOS REPORTS FIRST QUARTER 2018 RESULTS.Q1 REVENUE EUR 44.8 MILLION.QTRLY NET LOSS OF EUR 37.3 MILLION.QTRLY OPERATING LOSS EUR 32.0 MILLION.END OF Q1 CASH AND CASH EQUIVALENTS EUR 1.1 BILLION.GALAPAGOS EXPECTS AN OPERATIONAL CASH BURN BETWEEN €220 AND €240 MILLION IN 2018.CURRENT TOTAL CASH AND CASH EQUIVALENTS POSITION IS APPROXIMATELY EUR 1.1 BILLION.QTRLY BASIC AND DILUTED LOSS PER SHARE EUR 0.73.  Full Article

Galapagos FY Net Result Swings To Loss Of 115.7 Million Euros
Friday, 23 Feb 2018 02:15am EST 

Feb 23 (Reuters) - GALAPAGOS ::REPORTED ON THURSDAY FY NET LOSS OF €115.7 MILLION, COMPARED TO NET PROFIT OF €54.0 MILLION IN 2016.FY GROUP REVENUES INCREASED BY €4.3 MILLION TO €155.9 MILLION.FY OPERATING LOSS INCREASED BY €78.3 MILLION TO €89.8 MILLION.FY OPERATIONAL CASH BURN OF €154.1 MILLION.CASH BALANCE INCREASED BY €171.5 MILLION TO €1,152.4 MILLION AT YEAR-END.IN 2018 AIMS TO REPORT TOPLINE RESULTS WITH THE FINCH 2 (RHEUMATOID ARTHRITIS), EQUATOR (PSORIATIC ARTHRITIS), TORTUGA (ANKYLOSING SPONDILITIS) FILGOTINIB TRIALS AS WELL AS A DECISION TO CONTINUE TO PHASE 3 IN SELECTION (ULCERATIVE COLITIS).IN 2018 COLLABORATION PARTNER GILEAD EXPECTS TO COMPLETE RECRUITMENT OF FINCH 1 AND FINCH 3, THE REMAINING RA PHASE 3 TRIALS WITH FILGOTINIB.IN 2018 IN CYSTIC FIBROSIS WE ANTICIPATE THE READOUT OF THE PELICAN PATIENT TRIAL AND AN INTERIM READOUT IN FALCON.IN 2018 AIMS TO INITIATE PIVOTAL TRIALS WITH GLPG1690 (IPF) AND PHASE 2 TRIALS WITH GLPG1205 (IPF), AN ADDITIONAL CF TRIPLE COMBINATION, GLPG1972 (OSTEOARTHRITIS), AND MOR106 (ATOPIC DERMATITIS).EXPECTS AN OPERATIONAL CASH BURN BETWEEN €220 AND €240 MILLION IN 2018.  Full Article

Morphosys And Galapagos Present Results From Phase 1 Study With Mor106
Monday, 19 Feb 2018 03:04am EST 

Feb 19 (Reuters) - MORPHOSYS AG ::SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT.IN THE STUDY, MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS(AD)PATIENTS.83% OF PATIENTS (5 OUT OF 6) AT THE HIGHEST DOSE REACHED AT LEAST 50% IMPROVEMENT PER THE ATOPIC DERMATITIS AREA AND SEVERITY INDEX (EASI-50) AT WEEK 4.POOLED DATA ACROSS ALL DOSE COHORTS SHOWED 72% IMPROVEMENT OF AD SYMPTOMS AT WEEK 12 COMPARED TO BASELINE IN PATIENTS TREATED WITH MOR106.PHASE 2 DEVELOPMENT OF MOR106 PLANNED TO BE INITIATED IN FIRST HALF OF 2018.  Full Article

ProQR And Galapagos Announce Research Collaboration
Monday, 8 Jan 2018 07:00am EST 

Jan 8 (Reuters) - Galapagos Nv ::PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY.PROQR THERAPEUTICS - UNDER AGREEMENT, TWO COMPANIES WILL WORK TOGETHER TO DISCOVER NOVEL AXIOMER EONS AGAINST FIBROSIS TARGETS SELECTED BY GALAPAGOS.PROQR THERAPEUTICS NV- TARGETS THAT WILL BE PURSUED IN COLLABORATION AND FINANCIAL DETAILS ABOUT COLLABORATION ARE NOT DISCLOSED.  Full Article

Galapagos NV reports Q3 loss of ‍1.75​ euro per share
Thursday, 26 Oct 2017 04:01pm EDT 

Oct 26 (Reuters) - Galapagos NV -:Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​.Galapagos NV qtrly loss per share ‍1.75​ euro.Galapagos NV says ‍we anticipate cash burn for full year to be at lower end of guidance of euro 135 million - 155 million​.  Full Article

Galapagos says GLPG1690 halts disease progression in IPF patients in mid-stage trial
Wednesday, 9 Aug 2017 04:01pm EDT 

Aug 9 (Reuters) - Galapagos Nv :GLPG1690 halts disease progression in IPF patients in Flora phase 2A trial.Galapagos NV says GLPG1690 was generally well tolerated.Galapagos NV - ‍GLPG1690 expected to progress to late stage trial​.Galapagos NV -‍ rates of discontinuation due to adverse events, as well as serious adverse event rates, were similar between patients on GLPG1690, placebo​.  Full Article

Galapagos confirms FY cash burn guidance within range of €135 mln to €155 mln
Monday, 31 Jul 2017 04:50pm EDT 

July 31 (Reuters) - Galapagos Nv -:Galapagos NV says confirm cash burn guidance for the full year within the range of € 135 million – € 155 million - sec filing.  Full Article

Galapagos H1 revenues up at EUR 73.0 mln
Friday, 28 Jul 2017 04:47am EDT 

July 28 (Reuters) - GALAPAGOS ::ANNOUNCED ON THURSDAY H1 REVENUES EUR 73.0 MLN VS EUR 48.8 MLN YEAR AGO.H1 OPERATING LOSS EUR 32.9 MLN VS LOSS OF EUR 24.3 MLN YEAR AGO.H1 NET LOSS EUR 49.2 MLN VS PROFIT OF EUR 32.2 MLN YEAR AGO.CASH POSITION AT JUNE 30 EUR 1.26 BLN VS EUR 968.5 MLN YEAR AGO.CONFIRMS CASH BURN GUIDANCE FOR THE FULL YEAR WITHIN THE RANGE OF EUR 135–155 MILLION.  Full Article

Servier announces it has exercised option to develop osteoarthritis molecule from Galapagos
Thursday, 27 Jul 2017 04:00pm EDT 

July 27 (Reuters) - GALAPAGOS NV ::SERVIER ANNOUNCES IT HAS EXERCISED OPTION TO DEVELOP NOVEL OSTEOARTHRITIS MOLECULE GLPG1972/S201086 FROM GALAPAGOS NV, OBTAINING GLOBAL COMMERCIAL RIGHTS OUTSIDE THE U.S..TO RECEIVE €6 MILLION LICENSE FEE FROM SERVIER AND ELIGIBLE TO TOTAL OF €290 MILLION IN SUCCESS-BASED MILESTONES FROM COLLABORATION.  Full Article

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES